An update on DPP-4 inhibitors in the management of type 2 diabetes.

@article{Cahn2016AnUO,
  title={An update on DPP-4 inhibitors in the management of type 2 diabetes.},
  author={Avivit Cahn and Simona Cernea and Itamar Raz},
  journal={Expert opinion on emerging drugs},
  year={2016},
  volume={21 4},
  pages={409-419}
}
INTRODUCTION DPP-4 inhibitors are a class of compounds used for the treatment of type 2 diabetes. The drugs inhibit the degradation of GLP-1, thus amplifying the incretin effect. They have moderate glycemic efficacy, a low propensity of causing hypoglycaemia and are weight neutral. The drugs are often used as second line therapy after metformin. Areas covered: This review summarizes the available compounds in the market and discusses the novel compounds that are currently under development… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS